Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
Ocuphire Pharma to Present at the Aegis Virtual Conference
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting [Yahoo! Finance]
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery [Yahoo! Finance]